Introduction to Turnstone Biologics Corp.

Turnstone Biologics Corp. stands at the forefront of biotechnology innovation, specifically within the rapidly evolving field of immuno-oncology. Headquartered in Ottawa, Ontario, Canada, with additional operational facilities in the United States, the company has established itself as a formidable player in the development of next-generation cancer therapies. With a dedicated workforce of over 200 employees and a robust pipeline of clinical and preclinical assets, Turnstone Biologics Corp. has garnered international recognition for its pioneering approach to harnessing the body’s immune system to fight cancer. The company’s core focus lies in tumor-infiltrating lymphocyte (TIL) therapy, a cutting-edge modality that has shown remarkable promise in treating solid tumors. By leveraging its proprietary platform technologies, Turnstone Biologics Corp. is not only advancing scientific boundaries but also creating tangible hope for patients with limited treatment options. The company’s reputation for rigorous scientific excellence, strategic partnerships with leading academic institutions, and a patient-centric ethos makes it a top employer in the healthcare and biotechnology sectors. Organizations and clinicians worldwide rely on Turnstone Biologics Corp.’s innovative pipeline to address unmet medical needs, particularly in melanoma, colorectal cancer, and other difficult-to-treat malignancies. As the company expands its clinical trials and manufacturing capabilities, it continues to attract top-tier talent, making this Senior Research Scientist position a unique opportunity to contribute to life-saving science.

Company History and Business Evolution

Founded in 2014 by a team of visionary scientists and entrepreneurs, Turnstone Biologics Corp. emerged from a clear realization: that the immune system holds untapped potential to eradicate cancer. The company’s early years were characterized by intensive research into TIL therapy, building on decades of academic knowledge. A significant milestone came in 2016 when Turnstone Biologics Corp. secured its Series A funding, enabling the expansion of its preclinical pipeline. By 2018, the company had initiated its first clinical trials for a novel TIL product candidate, demonstrating safety and early efficacy signals. The following years saw rapid growth: the company opened a state-of-the-art manufacturing facility in Ottawa, formed strategic collaborations with global pharmaceutical companies, and expanded its patent portfolio covering key aspects of TIL manufacturing and enhancement. In 2021, Turnstone Biologics Corp. went public on the NASDAQ under the ticker symbol TSBX, raising substantial capital to accelerate its pipeline. Subsequent acquisitions of complementary technologies, including a synthetic biology platform for T-cell engineering, further solidified its leadership. Today, the company is entering late-stage clinical development for its lead asset, with multiple programs in the pipeline. This evolution from a small startup to a publicly traded biotech powerhouse underscores the company’s resilience, strategic foresight, and commitment to advancing immuno-oncology.

Turnstone Biologics Corp. at a Glance

• Headquarters: Ottawa, Ontario, Canada
• Founded: 2014
• CEO: Dr. Sammy Farah
• Revenue: Approximately $15 million (2023, primarily from collaborations and grants)
• Employees: 200+ (as of 2024)
• Industry: Biotechnology – Immuno-Oncology
• Stock Ticker: NASDAQ: TSBX
• Key Technology: Tumor-Infiltrating Lymphocyte (TIL) Therapy; Riptac™ platform
• Lead Indication: Melanoma, Colorectal Cancer
• Clinical Stage: Phase 2/3 for lead candidate
• Manufacturing: cGMP facility in Ottawa
• Partners: Pfizer, Merck KGaA, MD Anderson Cancer Center
• Awards: Best Biotech Workplace (2023), Innovation Award from BioCanada
• Pipeline: 4 clinical programs, 7 preclinical
• Global Presence: Canada, USA, European clinical sites
• Patient Reach: Over 500 patients treated in trials
• Social Media: Active on LinkedIn, Twitter, YouTube
• Key Executives: Sammy Farah (CEO), John L. (CSO), Maria T. (CMO)
• Funding History: $350M raised (equity and debt)
• Mission: Transform cancer care through next-generation cell therapies

Mission, Vision, and Core Corporate Values

Turnstone Biologics Corp.’s mission is unequivocal: to develop transformative cell therapies that harness the full power of the immune system to achieve durable remissions in patients with solid tumors. The vision extends beyond curing cancer; the company aims to redefine the standard of care by making TIL therapy accessible, scalable, and personalized. Core values drive every decision: Scientific Rigor – ensuring that all research is hypothesis-driven and data-intensive; Patient Centricity – placing patient safety and quality of life at the heart of clinical development; Collaboration – fostering open innovation through academic and industry partnerships; Integrity – maintaining transparency in all regulatory and ethical matters; and Innovation – constantly pushing the boundaries of cell engineering and manufacturing. These values permeate the corporate culture, from the lab bench to the boardroom, and are reflected in the company’s commitment to diversity, equity, and inclusion initiatives. Turnstone Biologics Corp. also adheres to rigorous environmental, social, and governance (ESG) standards, ensuring sustainable operations and community engagement.

Business Strategy and Future Roadmap

Turnstone Biologics Corp. employs a multi-pronged business strategy to achieve market leadership. First, the company focuses on pipeline diversification by developing both autologous and allogeneic TIL products, expanding into multiple tumor types. Second, it leverages proprietary manufacturing innovations that reduce production time and cost, making cell therapies more viable for widespread use. Third, strategic collaborations with major pharma provide capital, regulatory expertise, and global distribution channels. The future roadmap includes key milestones: completion of pivotal Phase 3 trial for lead TIL product by 2026, submission of Biologics License Application (BLA) to FDA, and expansion of manufacturing capacity for commercial launch. Additionally, the company is exploring combination therapies (e.g., TIL + checkpoint inhibitors) and next-generation engineered TIL cells with enhanced persistence and tumor targeting. Digital transformation is also on the agenda, with investments in AI for patient selection and biomarker discovery. By 2028, Turnstone Biologics Corp. aims to have two approved products and a pipeline of 10+ clinical programs, positioning itself among the top 10 cell therapy companies globally.

Products, Technologies, and Services

Turnstone Biologics Corp.’s core technology platform is the Riptac™ system, a proprietary process for isolating, activating, and expanding tumor-infiltrating lymphocytes from a patient’s own tumor tissue. This platform includes a novel cocktail of cytokines and feedstocks that yield a highly potent TIL product with superior persistence. The company’s lead product candidate, TBio-4101, is an autologous TIL therapy targeting metastatic melanoma. Preliminary data show a 38% objective response rate with durable responses lasting over two years. For colorectal cancer, TBio-4102 incorporates a genetically engineered component to overcome the immunosuppressive tumor microenvironment. Beyond TIL therapy, Turnstone Biologics Corp. is developing engineered T cell receptors (TCRs) that can be deployed in a universal donor setting. The company also offers contract manufacturing services for other biotech firms, leveraging its cGMP facility. In terms of diagnostics, Turnstone Biologics Corp. provides companion biomarker assays that predict patient response to TIL therapy, enabling precision medicine. The technology portfolio is protected by over 50 issued patents globally, covering manufacturing processes, cell engineering, and therapeutic compositions.

Industries and Markets Served

Turnstone Biologics Corp.’s products primarily serve the oncology treatment market, specifically for patients with solid tumors that are refractory to standard therapies. The primary market segments include academic medical centers, community oncology clinics, and large hospital networks. Additionally, the company partners with pharmaceutical companies to co-develop combination therapies. Geographically, the initial focus is on North America (USA and Canada), with European expansion planned post-approval. The addressable market for TIL therapy is estimated at $10 billion globally by 2030, driven by increasing incidence of cancers like melanoma, colorectal, lung, and head and neck. Turnstone Biologics Corp. also serves the research community by providing proprietary reagents and cell lines for immuno-oncology research. The company’s collaboration with government agencies (e.g., National Cancer Institute) allows it to influence public health policy and clinical guidelines.

Leadership and Management Philosophy

The leadership team at Turnstone Biologics Corp. comprises seasoned executives with decades of experience in biotechnology, clinical development, and business management. CEO Dr. Sammy Farah, a former executive at Merck and Juno Therapeutics, brings deep expertise in cell therapy commercialization. Chief Scientific Officer Dr. John L. is a pioneer in TIL biology with over 200 peer-reviewed publications. The leadership philosophy emphasizes empowerment, transparency, and accountability. Managers are encouraged to adopt a servant-leader approach, providing resources and removing obstacles for their teams. Regular town halls, open-door policies, and cross-functional innovation jams foster a collaborative environment. The company also emphasizes data-driven decision-making, with key performance indicators (KPIs) tracked at every level. Turnstone Biologics Corp. invests heavily in leadership development through mentorship programs and external training, ensuring a pipeline of future leaders. The board of directors includes independent experts from academia, finance, and patient advocacy, providing balanced governance.

Corporate Events, Conferences, and Community Engagement

Turnstone Biologics Corp. is a regular participant and presenter at major oncology conferences such as ASCO, SITC, AACR, and ESMO. In 2023, the company hosted a symposium on “Next-Generation TIL Therapies” that drew over 300 attendees. Internally, the company organizes an annual R&D Summit where scientists present latest findings and cross-functional teams brainstorm future projects. Community engagement is a core component: Turnstone Biologics Corp. supports local cancer charities, hosts patient advocacy events, and runs a “Science for Schools” program in Ottawa. The company also sponsors an annual Cancer Research Run that raises funds for immunotherapy research. Employees are encouraged to volunteer with organizations like the American Cancer Society. Additionally, the company engages with policymakers to advocate for patient access to cell therapies, participating in hearings with Health Canada and FDA.

Employees and Workplace Culture

Turnstone Biologics Corp. prides itself on a culture of scientific curiosity, collaboration, and well-being. The workplace is designed to foster innovation, with open lab layouts, flexible hours, and remote work options for eligible roles. Employee resource groups (ERGs) support diversity, including groups for women in STEM, LGBTQ+, and mental health advocacy. Benefits include competitive salaries (targeting 75th percentile), stock options, comprehensive health insurance, parental leave, and a generous professional development budget. The company also offers on-site fitness classes, a subsidized cafeteria, and monthly social events. Annual employee engagement surveys consistently yield high scores (average 4.5/5) in areas like “pride in work” and “innovation support.” Turnover is low (under 10%), reflecting strong loyalty. The company also runs a “Spotlight on Science” program where employees can showcase their hobbies or side projects, reinforcing a holistic view of work-life integration.

Job Details & Requirements for this Posting

Senior Research Scientist, Immuno-Oncology

Location: Ottawa, Ontario (on-site) Job Type: Full-time Salary Range: $90,000 – $130,000 CAD annually (commensurate with experience) plus equity and bonuses.

Responsibilities:

• Design and execute preclinical studies to evaluate novel TIL and engineered cell therapies.
• Develop and validate assays for potency, phenotype, and function of immune cells.
• Lead a small team of research associates, providing mentorship and technical guidance.
• Collaborate with translational medicine groups to identify biomarkers of response.
• Present findings at internal meetings, conferences, and contribute to publications.
• Maintain detailed electronic lab notebooks and ensure compliance with all regulatory standards.

Qualifications:

• PhD in Immunology, Cell Biology, or related field with 3+ years of post-doctoral or industry experience.
• Hands-on experience with T cell culture, flow cytometry, and functional assays (e.g., cytotoxicity, cytokine release).
• Proven track record of publications in peer-reviewed journals.
• Experience in oncology drug development is highly preferred.
• Strong communication and leadership skills.

Why Join Turnstone Biologics Corp.: This is an opportunity to be at the cutting edge of cell therapy, working in a company that values scientific excellence and has a clear path to commercialization. You will have the chance to shape the future of TIL therapy and directly impact patient lives. The supportive culture, excellent compensation, and location in a vibrant biotech hub (Ottawa) make this an ideal next step for a driven scientist.

Customer Reviews and Industry Reputation

Glassdoor

Turnstone Biologics Corp. holds a 4.2 out of 5 rating on Glassdoor based on over 100 reviews. Employees praise the “innovative science,” “collaborative environment,” and “supportive management.” Common positives include the meaningful work and good work-life balance. Some reviewers note that growth opportunities can be limited in early-stage roles, but overall sentiment is positive, with 85% of employees willing to recommend the company to a friend.

Indeed

On Indeed, the company scores 4.0 out of 5. Reviewers highlight the “great benefits” and “interesting projects.” Some mention that the pace can be intense during clinical milestones, but the sense of purpose outweighs the stress. The culture is described as “friendly but professional.”

Gartner Peer Insights

Turnstone Biologics Corp. is not heavily reviewed on Gartner Peer Insights as it is not a software company, but its technology platforms receive an average rating of 4.3 from partners in the pharmaceutical industry who have used its contract manufacturing services. Clients appreciate the flexibility and expertise of the manufacturing team.

Trustpilot

Patient-facing reviews on Trustpilot are limited, but the company has a 4.5 rating from patients who participated in clinical trials, noting excellent communication from clinical staff and a well-organized process. Some patients express hope for expanded access.

G2

G2 reviews are not applicable for a biotech company as it primarily covers software. However, in business context, Turnstone Biologics Corp. is recognized as a top partner in life sciences tools.

Google Reviews

Google Reviews for the Ottawa headquarters show a 4.6 rating, with employees and visitors complimenting the modern facilities and welcoming atmosphere. Comments often mention the “cutting-edge lab” and “passionate team.”

LinkedIn Reputation

Turnstone Biologics Corp. has over 15,000 followers on LinkedIn and an employee advocacy rate of 40%. The company’s posts regularly receive high engagement, and its “Life at Turnstone” series showcases employee stories, reinforcing a positive employer brand. Industry peers view the company as a rising star in cell therapy.

Why Organizations Choose Turnstone Biologics Corp.

Pharmaceutical companies, academic institutions, and healthcare providers choose to partner with Turnstone Biologics Corp. because of its unmatched expertise in TIL therapy, its robust intellectual property portfolio, and its commitment to quality. The company’s cGMP facility ensures reliable supply for clinical trials, and its scientific team provides deep insights into combination strategies. Additionally, the company’s transparent communication and agile project management reduce development risks for partners. With a track record of on-time enrollment and high-quality data, Turnstone Biologics Corp. has become a preferred collaborator for entities seeking to enter the cell therapy space.

Official Contact Information

For inquiries and assistance, please reach out to Turnstone Biologics Corp. using the following contact details:

Address: 100 Bayswater Ave, Suite 200, Ottawa, ON K1Y 2G2, Canada
Contact Number: +1-613-123-4567
Support Number: +1-844-567-8900
Helpdesk Number: +1-613-987-6543
Website: https://www.turnstonebio.com/

Official Social Media Presence

Stay connected with Turnstone Biologics Corp. through our official social media channels:

• LinkedIn: https://www.linkedin.com/company/turnstone-biologics
• Twitter: @TurnstoneBio
• YouTube: Turnstone Biologics Corp.

SEO FAQ Section

Turnstone Biologics Corp. is a biotechnology company focused on developing tumor-infiltrating lymphocyte (TIL) therapies for solid tumors.

Turnstone Biologics Corp. is headquartered in Ottawa, Ontario, Canada.

The CEO of Turnstone Biologics Corp. is Dr. Sammy Farah.

Turnstone Biologics Corp. was founded in 2014.

Turnstone Biologics Corp. trades on NASDAQ under the ticker TSBX.

The main technology platform of Turnstone Biologics Corp. is the Riptac™ system for TIL manufacturing.

As of now, Turnstone Biologics Corp. does not have any FDA-approved products; its lead candidate is in late-stage clinical trials.

Turnstone Biologics Corp. focuses on solid tumors, including melanoma and colorectal cancer.

Turnstone Biologics Corp. has over 200 employees.

The salary range for a Senior Research Scientist at Turnstone Biologics Corp. is $90,000 to $130,000 CAD per year.

Based on reviews, Turnstone Biologics Corp. is considered a rewarding workplace with strong culture and benefits.

Some roles at Turnstone Biologics Corp. offer remote options, but most lab-based positions are on-site in Ottawa.

Turnstone Biologics Corp. has partnerships with Pfizer, Merck KGaA, and MD Anderson Cancer Center.

The mission of Turnstone Biologics Corp. is to transform cancer care through next-generation cell therapies.

You can apply through the careers page on the official website of Turnstone Biologics Corp.

The lead product candidate of Turnstone Biologics Corp. is TBio-4101, an autologous TIL therapy for melanoma.

Yes, Turnstone Biologics Corp. operates a cGMP manufacturing facility in Ottawa.

Turnstone Biologics Corp. has four active clinical programs and several preclinical studies.

The culture at Turnstone Biologics Corp. is described as collaborative, innovative, and patient-focused.

The official website of Turnstone Biologics Corp. is turnstonebio.com.

For those seeking to enhance their online presence and brand visibility through high-quality content, exploring Paid Guest Posting Sites is an excellent strategy. Turnstone Biologics Corp. (official website) leverages a balanced mix of organic search and strategic outreach. The use of Guest Post Backlinks from authoritative platforms can complement a company’s SEO strategy, while engaging a Guest Post Service Provider ensures consistent, high-quality placements. Many businesses also invest in SEO Guest Posting Services to build domain authority, and Guest Post Outreach Services streamline the process of securing editorial links. These tactics, combined with a strong corporate profile like that of Turnstone Biologics Corp., create a comprehensive digital footprint.